The first U.S. patients have been dosed in a clinical trial testing whether four experimental mRNA vaccine candidates can prevent infection with the virus that causes COVID-19 disease.
These are the findings of a study in mice led by researchers from NYU Langone Medical Center and its Perlmutter Cancer Center, and published online July 18 in Cell Reports.